ESR1 and breast carcinoma: RMC-6272 was effective in two ER+ breast cancer PDX models from patients who initially responded but progressed on hormone therapy, and both models harbor ESR1D538G, an activating ESR1 mutation that is associated with hormone resistance [21, 32].